Clinical Cancer Research, Vol 2, Issue 1 201-206, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological features

BJ Simpson, AD Ramage, MJ Hulme, DJ Burns, D Katsaros, SP Langdon and WR Miller
Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital Trust, Crewe Road, Edinburgh EH4 2XU, United Kingdom.

The regulatory subunits of protein kinase A, or cyclic AMP-binding proteins, were measured in a series of 107 human ovarian tumors (89 malignant, 7 borderline, and 11 benign tumors) and related to tumor clinicopathological features and patient survival. Total cyclic AMP-binding protein levels were not significantly different between malignant tumors and either borderline or benign tumors. However, serous tumors showed significantly higher levels of total cyclic AMP-binding proteins than other malignant tumors (P = 0.007). Poorly differentiated tumors also possessed significantly higher levels of binding proteins as compared with well/moderately differentiated tumors (P < 0.01). Retrospective analysis of follow-up data also revealed a significant trend for patients with high tumor cyclic AMP-binding proteins to have poorer survival (P = 0.03). Individual binding proteins were identified by photoaffinity labeling, and the RI (Mr 48,000) protein was expressed as a percentage of total cyclic AMP-binding proteins detected. The percentage of the RI protein was not significantly different among malignant, borderline, or benign pathologies and was not associated with tumor stage, differentiation, or debulk status. The percentage of RI was significantly increased in serous tumors compared to other common epithelial malignancies (P = 0.01). In malignant tumors there was a significant positive correlation between the percentage of the RI protein and total cyclic AMP-binding proteins (P = 0.01). These data indicate that high tumor levels of cyclic AMP-binding proteins are associated with serous histology, poor differentiation, and poor patient survival.

This article has been cited by other articles:

				L. Yang, H. Zhao, S.-W. Li, K. Ahrens, C. Collins, S. Eckenrode, Q.-g. Ruan, R. A. McIndoe, and J.-X. She Gene Expression Profiling during All-trans Retinoic Acid-Induced Cell Differentiation of Acute Promyelocytic Leukemia Cells J. Mol. Diagn., November 1, 2003; 5(4): 212 - 221. [Abstract] [Full Text] [PDF]

				Y. S. Cho and Y. S. Cho-Chung Antisense Protein Kinase A RI{alpha} Acts Synergistically with Hydroxycamptothecin to Inhibit Growth and Induce Apoptosis in Human Cancer Cells: Molecular Basis for Combinatorial Therapy Clin. Cancer Res., March 1, 2003; 9(3): 1171 - 1178. [Abstract] [Full Text] [PDF]

				Y. S. Cho, M.-K. Kim, L. Tan, R. Srivastava, S. Agrawal, and Y. S. Cho-Chung Protein Kinase A RI{alpha} Antisense Inhibition of PC3M Prostate Cancer Cell Growth: Bcl-2 Hyperphosphorylation, Bax Up-Regulation, and Bad-Hypophosphorylation Clin. Cancer Res., February 1, 2002; 8(2): 607 - 614. [Abstract] [Full Text] [PDF]

				Y. S. Cho, M.-K. Kim, C. Cheadle, C. Neary, K. G. Becker, and Y. S. Cho-Chung Antisense DNAs as multisite genomic modulators identified by DNA microarray PNAS, July 24, 2001; (2001) 171314398. [Abstract] [Full Text] [PDF]

				G. Tortora, R. Bianco, V. Damiano, G. Fontanini, S. De Placido, A. R. Bianco, and F. Ciardiello Oral Antisense that Targets Protein Kinase A Cooperates with Taxol and Inhibits Tumor Growth, Angiogenesis, and Growth Factor Production Clin. Cancer Res., June 1, 2000; 6(6): 2506 - 2512. [Abstract] [Full Text]

				H. X. Chen, J. L. Marshall, E. Ness, R. R. Martin, B. Dvorchik, N. Rizvi, J. Marquis, M. McKinlay, W. Dahut, and M. J. Hawkins A Safety and Pharmacokinetic Study of a Mixed-Backbone Oligonucleotide (GEM231) Targeting the Type I Protein Kinase A by Two-hour Infusions in Patients with Refractory Solid Tumors Clin. Cancer Res., April 1, 2000; 6(4): 1259 - 1266. [Abstract] [Full Text]

				H. Wang, Q. Cai, X. Zeng, D. Yu, S. Agrawal, and R. Zhang Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration PNAS, November 23, 1999; 96(24): 13989 - 13994. [Abstract] [Full Text] [PDF]

				G. Tortora, R. Caputo, G. Pomatico, S. Pepe, A. R. Bianco, S. Agrawal, J. Mendelsohn, and F. Ciardiello Cooperative Inhibitory Effect of Novel Mixed Backbone Oligonucleotide Targeting Protein Kinase A in Combination with Docetaxel and Anti-Epidermal Growth Factor-Receptor Antibody on Human Breast Cancer Cell Growth Clin. Cancer Res., April 1, 1999; 5(4): 875 - 881. [Abstract] [Full Text] [PDF]

				G. Tortora, R. Caputo, V. Damiano, R. Bianco, S. Pepe, A. R. Bianco, Z. Jiang, S. Agrawal, and F. Ciardiello Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A PNAS, November 11, 1997; 94(23): 12586 - 12591. [Abstract] [Full Text] [PDF]

				Y. S. Cho, M.-K. Kim, C. Cheadle, C. Neary, K. G. Becker, and Y. S. Cho-Chung Antisense DNAs as multisite genomic modulators identified by DNA microarray PNAS, August 14, 2001; 98(17): 9819 - 9823. [Abstract] [Full Text] [PDF]